FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). ☐ Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * Zauderer Maurice	2. Issuer Name and Ticker or Trading Symbol VACCINEX, INC. [ VCNX ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director                    __X__ 10% Owner __X__ Officer (give title below)    _____ Other (specify below) President and CEO
(Last)          (First)          (Middle) C/O VACCINEX, INC., 1895 MOUNT HOPE AVENUE	3. Date of Earliest Transaction (MM/DD/YYYY) 9/18/2024
(Street) ROCHESTER, NY 14620	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) ___ Form filed by One Reporting Person _ X _ Form filed by More than One Reporting Person
(City)        (State)        (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								1,580	D
Common Stock								1,016	I	By Jeremy C. Zauderer Trust (1)
Common Stock								1,011	I	By Jordan M. Zauderer Trust (1)
Common Stock	9/18/2024		M		38,610	A	$5.636 (3)	176,748	I	By Vaccinex (Rochester), L.L.C. (2)
Common Stock	9/18/2024		M		29,557	A	$5.636 (4)	206,305	I	By Vaccinex (Rochester), L.L.C. (2)
Common Stock	9/18/2024		M		9,768	A	$5.636 (5)	216,073	I	By Vaccinex (Rochester), L.L.C. (2)
Common Stock	9/18/2024		M		35,715	A	$5.636 (4)	251,788	I	By Vaccinex (Rochester), L.L.C. (2)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrant (Right to Buy)	$5.636 (3)	9/18/2024		M			38,610	3/28/2024	3/28/2029	Common Stock	38,610	$0	0	I	By Vaccinex (Rochester), L.L.C. (2)
Warrant (Right to Buy)	$5.636 (4)	9/18/2024		M			29,557	2/8/2024	2/8/2029	Common Stock	29,557	$0	0	I	By Vaccinex (Rochester), L.L.C. (2)
Warrant (Right to Buy)	$5.636 (5)	9/18/2024		M			9,768	11/2/2023	11/2/2028	Common Stock	9,768	$0	0	I	By Vaccinex (Rochester), L.L.C. (2)
Warrant (Right to Buy)	$5.636 (4)	9/18/2024		M			35,715	10/3/2023	10/3/2028	Common Stock	35,715	$0	0	I	By Vaccinex (Rochester), L.L.C. (2)
Warrant (Right to Buy)	$5.636	9/18/2024		A		170,475		9/18/2024	9/18/2029	Common Stock	170,475	$0.125	170,475	I	By Vaccinex (Rochester), L.L.C. (2)
Stock Option (Right to Buy)	$3,129							(6)	3/31/2024	Common Stock	12		12	D
Stock Option (Right to Buy)	$3,129							(6)	6/30/2024	Common Stock	12		12	D
Stock Option (Right to Buy)	$1,491							(6)	12/23/2025	Common Stock	15		15	D
Stock Option (Right to Buy)	$1,402.8							(6)	2/24/2025	Common Stock	135		135	D
Stock Option (Right to Buy)	$615.3							(7)	4/2/2031	Common Stock	66		66	D
Stock Option (Right to Buy)	$270.9							(8)	4/1/2032	Common Stock	133		133	D
Stock Option (Right to Buy)	$92.26							(9)	3/30/2028	Common Stock	266		266	D
Stock Option (Right to Buy)	$8.21							(10)	3/21/2034	Common Stock	1,877		1,877	D

Explanation of Responses:
(1)	Dr. Zauderer exercises voting control over shares held by this trust and disclaims beneficial ownership over these shares except to the extent of his pecuniary interest therein.
(2)	Dr. Zauderer is the president and a majority owner of Vaccinex (Rochester), L.L.C. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
(3)	This warrant was originally reported on Form 4 with an exercise price of $7.64. Pursuant to a warrant inducement agreement by and between the issuer and Vaccinex (Rochester) L.L.C. dated September 17, 2024 (the "Warrant Inducement Agreement"), the exercise price of this warrant was adjusted to $5.636.
(4)	This warrant was originally reported on Form 4 with an exercise price of $14.00. Pursuant to the Warrant Inducement Agreement, the exercise price of this warrant was adjusted to $5.636.
(5)	This warrant was originally reported on Form 4 with an exercise price of $32.76. Pursuant to the Warrant Inducement Agreement, the exercise price of this warrant was adjusted to $5.636.
(6)	Exercisable in full as of the date of this report.
(7)	This option vests one-fourth on each of the first four anniversaries of the April 2, 2021 grant date, except as otherwise provided in the award notice.
(8)	This option vests one-fourth on each of the first four anniversaries of the April 1, 2022 grant date, except as otherwise provided in the award notice.
(9)	This option vests one-fourth on each of the first four anniversaries of the March 31, 2023 grant date, except as otherwise provided in the award notice.
(10)	This option vests one-fourth on each of the first four anniversaries of the March 21, 2024 grant date, except as otherwise provided in the award notice.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Zauderer Maurice C/O VACCINEX, INC. 1895 MOUNT HOPE AVENUE ROCHESTER, NY 14620	X	X	President and CEO
Vaccinex (Rochester), L.L.C. 44 WOODLAND ROAD PITTSFORD, NY 14534		X

Signatures
/s/ Maurice Zauderer		9/20/2024
**Signature of Reporting Person		Date
Vaccinex (Rochester) L.L.C. By: /s/ Maurice Zauderer, President		9/20/2024
**Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.